Analystreport

Cytokinetics (NASDAQ:CYTK) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.

Cytokinetics, Incorporated  (CYTK) 
Last cytokinetics, incorporated earnings: 3/3 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview